Skip to main content
Clinical Trials/NCT06209983
NCT06209983
Active, not recruiting
Not Applicable

The Effect of Enhanced Recovery After Surgery (ERAS) in Gastric Cancer Surgery

National Taiwan University Hospital1 site in 1 country38 target enrollmentDecember 5, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anesthesiology
Sponsor
National Taiwan University Hospital
Enrollment
38
Locations
1
Primary Endpoint
Length of hospital stay
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

The investigators aimed to clarify the clinical relevance of the ERAS protocol by evaluating the perioperative course in patients undergoing laparoscopic gastric cancer surgery.

Detailed Description

Gastric cancer is 7th common malignant disease in Taiwan, accounting for 3000 new cases per year. The main treatment of gastric cancer is radical gastrectomy and lymph nodes dissection, which is associated with 13.0\~46 % of surgical morbidities. To minimize the surgical morbidities and enhance patients' recovery, perioperative management is mandatory. Enhanced Recovery After Surgery (ERAS) is a multimodal, multidisciplinary approach to the care of the surgical patient. ERAS process implementation involves a team consisting of surgeons, anesthetists, an ERAS coordinator, and staff from units that care for the surgical patient. The main elements of ERAS include carbohydrate loading before surgery, minimally invasive approaches, balanced management of intravenous fluids, multimodal pain management, early mobilization, and early oral feeding, etc. Some prospective studies have shown its effectiveness in reduce surgical morbidity and hospital stay in colorectal surgery. In Taiwan, there was only limited report to study the use of ERAS in gastric cancer surgery. The investigators would like to integrate these perioperative interventions into the ERAS program, and test its effectiveness in gastric cancer patients undergoing radical gastrectomy at NTUH.

Registry
clinicaltrials.gov
Start Date
December 5, 2018
End Date
December 31, 2027
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Pathological confirmed as gastric adenocarcinoma;
  • Gastric cancer patients who will undergo subtotal gastrectomy.

Exclusion Criteria

  • Advanced gastric cancer with gastric outlet obstruction;
  • Epidural catheter placement contraindicated or inexecutable;
  • Have other cancers that have received chemotherapy or radiation therapy;
  • Coagulation abnormalities;
  • Pregnancy;
  • Severe dysfunction of major organs (e.g., heart failure, chronic obstructive pulmonary disease, liver cirrhosis, end-stage renal disease)

Outcomes

Primary Outcomes

Length of hospital stay

Time Frame: From date of admission until the date of discharge, assessed up to 2 weeks.

When patient discharge.

Secondary Outcomes

  • Complication rates(28 days)

Study Sites (1)

Loading locations...

Similar Trials